Washington: A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment.In their report Massachusetts General Hospital (MGH) Cancer Center investigators describe finding that the HOXB13/IL17BR ratio can indicate which women are at risk for cancer recurrence after tamoxifen and which are most likely to benefit from continuing treatment with the aromatase inhibitor letrozole (Femara).
BRICS Summit, an opportunity to discuss vital issues: PM Modi
Controversy over Ved Pratap`s meeting with Hafiz Saeed
Sawan rituals begin; devotees swarm Shiv temples
UPSC aspirants protest outside Rajnath Singh`s residence